BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease

BioNews
Biotechnology, Pharmaceutical and Life Science News
search help
Search Results
Documents 1-2 out of 2 found
  Current Search:  leukoencephalopathy: 4, progressive: 95, multifocal: 29     
HTML
100%
Natalizumab: Risk of Developing Progressive Multifocal Leukoencephalopathy (PML) Increases With Increasing Dur
The FDA recently notified healthcare professionals that the risk of developing progressive multifocal leukoencephalopathy (PML) is higher with an increased number of natalizumab (Tysabri) infusions received.

This new safety information is based on reports of...

AAPS Pharmceutica:  Feb 12 2010 12:03AM
Matching: leukoencephalopathy progressive multifocal 		Find similar documents
HTML
100%
FDA Drug Safety Communication: Risk of Progressive Multifocal Leukoencephalopathy (PML) with the use of Tysabr
[02-05-2010] The U.S.

Food and Drug Administration (FDA) is alerting the public that the risk of developing progressive multifocal leukoencephalopathy (PML), a rare but serious brain infection associated with the use of Tysabri (natalizumab), increases with...

Pharma Live:  Feb 8 2010 12:58PM
Matching: leukoencephalopathy progressive multifocal 		Find similar documents

 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.

All rights reserved. All other trademarks recognized.
Copyright 1997-2009 - BioPortfolio Limited.